These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20102634)

  • 1. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
    Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
    Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
    Lucas TM; Lyddon TD; Cannon PM; Johnson MC
    J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
    Janaka SK; Lucas TM; Johnson MC
    J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional complementation of a model target to study Vpu sensitivity.
    Janaka SK; Faurot J; Johnson MC
    PLoS One; 2013; 8(6):e68507. PubMed ID: 23840857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
    PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
    Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
    Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
    Gustin JK; Douglas JL; Bai Y; Moses AV
    J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
    Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
    Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of β-TrcP-dependent ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in human T cells.
    Verma S; Ali A; Arora S; Banerjea AC
    Blood; 2011 Jun; 117(24):6600-7. PubMed ID: 21521785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors.
    Christodoulopoulos I; Cannon PM
    J Virol; 2001 May; 75(9):4129-38. PubMed ID: 11287562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.
    Tokarev AA; Munguia J; Guatelli JC
    J Virol; 2011 Jan; 85(1):51-63. PubMed ID: 20980512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Compound Inhibitors of HIV-1
    Robinson CA; Lyddon TD; Gil HM; Evans DT; Kuzmichev YV; Richard J; Finzi A; Welbourn S; Rasmussen L; Nebane NM; Gupta VV; Ananthan S; Cai Z; Wonderlich ER; Augelli-Szafran CE; Bostwick R; Ptak RG; Schader SM; Johnson MC
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
    Blanchet FP; Mitchell JP; Piguet V
    Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.